Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01170065
Registration number
NCT01170065
Ethics application status
Date submitted
6/07/2010
Date registered
27/07/2010
Date last updated
6/06/2019
Titles & IDs
Public title
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Query!
Scientific title
A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Query!
Secondary ID [1]
0
0
2009-013788-21
Query!
Secondary ID [2]
0
0
1199.35
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BIBF 1120
Treatment: Drugs - BIBF 1120
Treatment: Drugs - BIBF 1120
Treatment: Drugs - BIBF 1120
Experimental: BIBF 1120 low qd - Low dose BIBF 1120 once daily
Experimental: BIBF 1120 low bid - Low dose BIBF 1120 twice daily
Experimental: BIBF 1120 medium bid - Intermediate dose BIBF 1120 twice daily
Experimental: BIBF 1120 high bid - High dose BIBF 1120 twice daily
Treatment: Drugs: BIBF 1120
Intermediate dose BIBF 1120 twice daily
Treatment: Drugs: BIBF 1120
High dose BIBF 1120 twice daily
Treatment: Drugs: BIBF 1120
Low dose BIBF 1120 twice daily
Treatment: Drugs: BIBF 1120
Low dose BIBF 1120 once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annual Rate of Decline in Forced Vital Capacity (FVC)
Query!
Assessment method [1]
0
0
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate.
Query!
Timepoint [1]
0
0
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Query!
Secondary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival is defined as the time from the first intake of nintedanib in trial 1199.35 to death.
For presentation of overall survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment survival is calculated within each treatment arm.
Query!
Timepoint [1]
0
0
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Query!
Secondary outcome [2]
0
0
Progression-Free Survival
Query!
Assessment method [2]
0
0
Progression-free survival was defined as the time from the first nintedanib intake in trial 1199.35 to disease progression.
For presentation of progression-free survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment progression-free survival is calculated within each treatment arm.
Query!
Timepoint [2]
0
0
From first trial drug intake in 1199.35 to disease progression; up to 61.8 months
Query!
Secondary outcome [3]
0
0
Annual Rate of Decline in Haemoglobin Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Decrease
Query!
Assessment method [3]
0
0
Haemoglobin corrected DLCO decrease was a secondary endpoint for the trial. It was considered important that all investigators used the same method of testing and recording data at each visit for each patient.
Haemoglobin corrected DLCO was calculated for each patient using the following formulae:
Males: Hb corrected DLCO = measured DLCO x (10.22 + Hb concentration) / (1.7 x Hb concentration) Females: Hb corrected DLCO = measured DLCO x (9.38 + Hb concentration) / (1.7 x Hb concentration). Annual rate of decline in haemoglobin corrected diffusing capacity of the lung for carbon monoxide (DLCO) decrease is presented.
Query!
Timepoint [3]
0
0
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Query!
Secondary outcome [4]
0
0
Percentage of Patients With at Least One Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Query!
Assessment method [4]
0
0
Percentage of patients with at least one acute idiopathic pulmonary fibrosis (IPF) exacerbation are presented.
An exacerbation was defined as otherwise unexplained clinical features occurring within
1 month including all of the following:
* Progression of dyspnoea over several days to 4 weeks
* New diffuse pulmonary infiltrates on chest X-ray and/or high-resolution computerised tomography (HRCT) Parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit
* A decrease in arterial oxygen partial pressure (PaO2) of =10 mmHg or PaO2/fraction of inspired oxygen (FiO2) of \<225 mmHg since the last visit
* Exclusion of infection based on routine clinical practice and microbiological studies
* Absence of other contributory causes such as congestive heart failure, pulmonary embolism, etc.
Query!
Timepoint [4]
0
0
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Query!
Secondary outcome [5]
0
0
Incidence of Patients With at Least One Acute IPF Exacerbation Over Time
Query!
Assessment method [5]
0
0
Incidence rate = (Patients with at least one acute IPF exacerbation / Total number of years at risk) x 100
Query!
Timepoint [5]
0
0
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Query!
Secondary outcome [6]
0
0
Time to First Acute IPF Exacerbation
Query!
Assessment method [6]
0
0
Due to rare events, the median of time to event is not calculable, thus Kaplan-Meier estimates (providing the percentage of patients without acute IPF exacerbation for a certain amount of time after treatment) and confidence intervals (using Greenwood variance formula) are reported and presented within each treatment arm as secondary endpoint.
Query!
Timepoint [6]
0
0
From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months
Query!
Secondary outcome [7]
0
0
Percentage of Patients With at Least One Adverse Events (AEs), With Investigator Defined Drug-Related AEs, AEs Leading to Discontinuation of Trial Drug, Serious AEs
Query!
Assessment method [7]
0
0
Percentage of patients with at least one Adverse events (AEs), with investigator defined drug-related AEs, AEs leading to discontinuation of trial drug, serious AEs are presented
Query!
Timepoint [7]
0
0
From the first nintedanib intake in trial 1199.35 to the last nintedanib intake + 28 days; up to 61.8 months + 28 days
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
1. Patient with a primary diagnosis of IPF (according to the 2000 American Thoracic Society/European Respiratory Society (ATS/ERS) criteria, who are willing to continue trial medication.
2. Written informed consent signed prior to entry into the study, in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local law
3. Completion of 1199.30 study and still under treatment (i.e. not discontinued in parent trial)
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
1. Any disease that may put the patient at risk when participating in this trial. Reconsider carefully all exclusion criteria of trial 1199.30. However, patients may qualify for participation even though exclusion criteria may have been met during the course of participation in 1199.30, if the investigator's benefit-risk assessment remains favourable.
2. Participation in another experimental clinical trial (except 1199.30) in the last 8 weeks.
3. Women who are breast feeding or of child bearing potential not using a highly effective method of birth control for at least one month prior to inclusion and at least 10 weeks after end of active therapy.
Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1 % per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some Intra Uterine Devices (IUDs), sexual abstinence or vasectomized partner. Female patients will be considered of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.
4. Sexually active males not committing to using condoms during the course of the study and at least 10 weeks after the end of active therapy (except if their partner is not of childbearing potential).
5. Patients who require full-dose anticoagulation (e.g. vitamin K antagonists, heparin, hirudin etc).
6. Patients who require full-dose antiplatelet (e.g. acetyl salicylic acid, clopidogrel etc) therapy.
7. Known or suspected active alcohol or drug abuse.
8. Patient not compliant in previous trial, with trial medication or trial visits.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/06/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/09/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
198
Query!
Recruitment in Australia
Recruitment state(s)
SA,WA
Query!
Recruitment hospital [1]
0
0
Respiratory Clinical Trial Pty Ltd. - Glen Osmond
Query!
Recruitment hospital [2]
0
0
The Queen Elizabeth Hospital - Woodville
Query!
Recruitment hospital [3]
0
0
Royal Perth Hospital-Lung Transplant Unit - Perth
Query!
Recruitment postcode(s) [1]
0
0
5064 - Glen Osmond
Query!
Recruitment postcode(s) [2]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [3]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Mendoza
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Bruxelles
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Leuven
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Yvoir
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Porto Alegre
Query!
Country [6]
0
0
Bulgaria
Query!
State/province [6]
0
0
Sofia
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Nova Scotia
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Ontario
Query!
Country [9]
0
0
Chile
Query!
State/province [9]
0
0
Santiago
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Beijing
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Nanjing
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Shanghai
Query!
Country [13]
0
0
Czechia
Query!
State/province [13]
0
0
Prague 8
Query!
Country [14]
0
0
Czechia
Query!
State/province [14]
0
0
Usti nad Labem
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Bobigny
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
DIJON Cedex
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Lille Cedex
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Lille
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Montpellier
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Nice Cedex 1
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Paris Cedex 18
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Donaustauf
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Essen
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Freiburg/Breisgau
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Großhansdorf
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Mainz
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
München
Query!
Country [28]
0
0
Greece
Query!
State/province [28]
0
0
Alexandroupolis
Query!
Country [29]
0
0
Greece
Query!
State/province [29]
0
0
Heraklion
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Deszk
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Pecs
Query!
Country [32]
0
0
Ireland
Query!
State/province [32]
0
0
Dublin
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Ascoli Piceno
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Milano
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Modena
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Napoli
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Roma
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Siena
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Terni
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Trieste
Query!
Country [41]
0
0
Mexico
Query!
State/province [41]
0
0
Distrito Federal
Query!
Country [42]
0
0
Netherlands
Query!
State/province [42]
0
0
Nieuwegein
Query!
Country [43]
0
0
Portugal
Query!
State/province [43]
0
0
Coimbra
Query!
Country [44]
0
0
Portugal
Query!
State/province [44]
0
0
Lisboa
Query!
Country [45]
0
0
Portugal
Query!
State/province [45]
0
0
Porto
Query!
Country [46]
0
0
Russian Federation
Query!
State/province [46]
0
0
Moscow
Query!
Country [47]
0
0
Russian Federation
Query!
State/province [47]
0
0
St. Petersburg
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Barcelona
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Valencia
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Birmingham
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
Manchester
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
Westbury On Trym
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug. The primary objective will be to establish the long term tolerability and safety profile of BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF). As a secondary objective the effects of long term treatment with BIBF 1120 on survival as well as safety and efficacy parameters will be investigated in an open-label, not randomized, un-controlled design.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01170065
Query!
Trial related presentations / publications
Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01170065
Download to PDF